255 related articles for article (PubMed ID: 33058670)
1. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
2. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
[TBL] [Abstract][Full Text] [Related]
3. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
Yang M; Xiang H; Luo G
Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
Lv P; Chen K; Zhu HL
Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
6. Computational-based discovery of FAK FERM domain chemical probes that inhibit HER2-FAK cancer signaling.
Stahl E; Nott R; Koessel K; Cance W; Marlowe T
Chem Biol Drug Des; 2020 Jun; 95(6):584-599. PubMed ID: 32080977
[TBL] [Abstract][Full Text] [Related]
7. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
Chauhan A; Khan T
Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase regulates collagen I-induced airway smooth muscle phenotype switching.
Dekkers BG; Spanjer AI; van der Schuyt RD; Kuik WJ; Zaagsma J; Meurs H
J Pharmacol Exp Ther; 2013 Jul; 346(1):86-95. PubMed ID: 23591997
[TBL] [Abstract][Full Text] [Related]
10. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
[TBL] [Abstract][Full Text] [Related]
11. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
[TBL] [Abstract][Full Text] [Related]
12. FAK inhibitors in Cancer, a patent review.
Lv PC; Jiang AQ; Zhang WM; Zhu HL
Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase as a cancer therapy target.
Golubovskaya VM
Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
[TBL] [Abstract][Full Text] [Related]
14. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase.
Yen-Pon E; Li B; Acebrón-Garcia-de-Eulate M; Tomkiewicz-Raulet C; Dawson J; Lietha D; Frame MC; Coumoul X; Garbay C; Etheve-Quelquejeu M; Chen H
ACS Chem Biol; 2018 Aug; 13(8):2067-2073. PubMed ID: 29897729
[TBL] [Abstract][Full Text] [Related]
16. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights.
Yoon H; Dehart JP; Murphy JM; Lim ST
J Histochem Cytochem; 2015 Feb; 63(2):114-28. PubMed ID: 25380750
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase inhibitors are potent anti-angiogenic agents.
Cabrita MA; Jones LM; Quizi JL; Sabourin LA; McKay BC; Addison CL
Mol Oncol; 2011 Dec; 5(6):517-26. PubMed ID: 22075057
[TBL] [Abstract][Full Text] [Related]
18. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.
Wu X; Wang J; Liang Q; Tong R; Huang J; Yang X; Xu Y; Wang W; Sun M; Shi J
Biomed Pharmacother; 2022 Jul; 151():113116. PubMed ID: 35598365
[TBL] [Abstract][Full Text] [Related]
19. FAK signaling in human cancer as a target for therapeutics.
Lee BY; Timpson P; Horvath LG; Daly RJ
Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
